Fig. 6
From: Spatially fractionated GRID radiation potentiates immune-mediated tumor control
SFRT-GRID leads to clearance when Tx is sufficiently immunogenic. Parameter set 13: A.i. Cancer-effector plane dynamics and snapshots of mIHC slides 12 and 63 treated with 2 Gy × 35 SFRT-GRID (30:70). A.ii. Snapshots of representative simulations of mIHC slides 12 and 63 at the end of week 1 (top row), and tumor clearance (bottom row). B.i. Cancer-effector plane dynamics and snapshots of mIHC slides 12 and 63 treated with 2 Gy × 35 SFRT-GRID (50:50). B.ii. Snapshots of representative simulations of mIHC slides 12 and 63 at the end of week 1 (top row), and tumor clearance (bottom row). Parameter set 15: C.i. Cancer-effector plane dynamics and snapshots of mIHC slides 12 and 63 treated with 2 Gy × 35 SFRT-GRID (30:70). C.ii. Snapshots of representative simulations of mIHC slides 12 and 63 at the end of week 1 (top row), and week 15 (bottom row). D.i. Cancer-effector plane dynamics and snapshots of mIHC slides 12 and 63 treated with 2 Gy × 35 SFRT-GRID (50:50). D.ii. Snapshots of representative simulations of mIHC slides 12 and 63 at the end of week 1 (top row), and week 15 (bottom row). See Fig. S7 for snapshots of mIHC slides 28 and 93